Management of Post-COVID-19-Related Olfactory Dysfunction
Autor(a) principal: | |
---|---|
Data de Publicação: | 2022 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://scielo.pt/scielo.php?script=sci_arttext&pid=S2184-06282022000300221 |
Resumo: | Abstract Evidence suggests that the prevalence of olfactory dysfunction (OD) occurs in 50% of patients with COVID-19. Emerging data suggest a high rate of early and spontaneous recovery, but approximately 10% of patients showed no improvement at 4-6 weeks after recovery. Given the high prevalence of COVID-19, a considerable number of patients will experience this morbidity. Thus, the main goal of this review is to define a guideline protocol for patients recovered from COVID-19, who present with olfactory dysfunction. In those cases, it is important to start by classifying the severity of this change and rule out other possible underlying etiologies, which may require further investigation. The treatment with best results is olfactory training. Additionally, the use of nasal corticosteroid spray or omega-3 supplementation may be recommended. It should be noted that those conclusions are based upon clinical trials whose patients were infected by viruses other than SARS-CoV-2. This way, further study and validation regarding the treatment of this condition should be carried out as the pandemic progresses. |
id |
RCAP_e3c75d51f9423e90a27d5cba3cc6a8ba |
---|---|
oai_identifier_str |
oai:scielo:S2184-06282022000300221 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Management of Post-COVID-19-Related Olfactory DysfunctionCOVID-19/complicationsOlfaction Disorders/drug therapyOlfaction Disorders/etiologyAbstract Evidence suggests that the prevalence of olfactory dysfunction (OD) occurs in 50% of patients with COVID-19. Emerging data suggest a high rate of early and spontaneous recovery, but approximately 10% of patients showed no improvement at 4-6 weeks after recovery. Given the high prevalence of COVID-19, a considerable number of patients will experience this morbidity. Thus, the main goal of this review is to define a guideline protocol for patients recovered from COVID-19, who present with olfactory dysfunction. In those cases, it is important to start by classifying the severity of this change and rule out other possible underlying etiologies, which may require further investigation. The treatment with best results is olfactory training. Additionally, the use of nasal corticosteroid spray or omega-3 supplementation may be recommended. It should be noted that those conclusions are based upon clinical trials whose patients were infected by viruses other than SARS-CoV-2. This way, further study and validation regarding the treatment of this condition should be carried out as the pandemic progresses.Círculo Médico2022-09-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articletext/htmlhttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2184-06282022000300221Gazeta Médica v.9 n.3 2022reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPenghttp://scielo.pt/scielo.php?script=sci_arttext&pid=S2184-06282022000300221Gomes,Catarina CastroSoutinho,JoanaPereira,Ana Luísainfo:eu-repo/semantics/openAccess2024-02-06T17:32:17Zoai:scielo:S2184-06282022000300221Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T02:35:05.601442Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Management of Post-COVID-19-Related Olfactory Dysfunction |
title |
Management of Post-COVID-19-Related Olfactory Dysfunction |
spellingShingle |
Management of Post-COVID-19-Related Olfactory Dysfunction Gomes,Catarina Castro COVID-19/complications Olfaction Disorders/drug therapy Olfaction Disorders/etiology |
title_short |
Management of Post-COVID-19-Related Olfactory Dysfunction |
title_full |
Management of Post-COVID-19-Related Olfactory Dysfunction |
title_fullStr |
Management of Post-COVID-19-Related Olfactory Dysfunction |
title_full_unstemmed |
Management of Post-COVID-19-Related Olfactory Dysfunction |
title_sort |
Management of Post-COVID-19-Related Olfactory Dysfunction |
author |
Gomes,Catarina Castro |
author_facet |
Gomes,Catarina Castro Soutinho,Joana Pereira,Ana Luísa |
author_role |
author |
author2 |
Soutinho,Joana Pereira,Ana Luísa |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Gomes,Catarina Castro Soutinho,Joana Pereira,Ana Luísa |
dc.subject.por.fl_str_mv |
COVID-19/complications Olfaction Disorders/drug therapy Olfaction Disorders/etiology |
topic |
COVID-19/complications Olfaction Disorders/drug therapy Olfaction Disorders/etiology |
description |
Abstract Evidence suggests that the prevalence of olfactory dysfunction (OD) occurs in 50% of patients with COVID-19. Emerging data suggest a high rate of early and spontaneous recovery, but approximately 10% of patients showed no improvement at 4-6 weeks after recovery. Given the high prevalence of COVID-19, a considerable number of patients will experience this morbidity. Thus, the main goal of this review is to define a guideline protocol for patients recovered from COVID-19, who present with olfactory dysfunction. In those cases, it is important to start by classifying the severity of this change and rule out other possible underlying etiologies, which may require further investigation. The treatment with best results is olfactory training. Additionally, the use of nasal corticosteroid spray or omega-3 supplementation may be recommended. It should be noted that those conclusions are based upon clinical trials whose patients were infected by viruses other than SARS-CoV-2. This way, further study and validation regarding the treatment of this condition should be carried out as the pandemic progresses. |
publishDate |
2022 |
dc.date.none.fl_str_mv |
2022-09-01 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S2184-06282022000300221 |
url |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S2184-06282022000300221 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
http://scielo.pt/scielo.php?script=sci_arttext&pid=S2184-06282022000300221 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
text/html |
dc.publisher.none.fl_str_mv |
Círculo Médico |
publisher.none.fl_str_mv |
Círculo Médico |
dc.source.none.fl_str_mv |
Gazeta Médica v.9 n.3 2022 reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799137405604724736 |